Cancer informatics analysis indicates high CHAC2 associated with unfavorable prognosis in breast cancer

Breast cancer remains the most commonly diagnosed cancer worldwide and exhibits a poor prognosis. The induction of genetic changes deregulates several genes that increase the disposal towards this life-threatening disease. CHAC2, a member of the glutathione degrading enzyme family has been shown to...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 1058931
Main Authors Chand, Subhash, Mehta, Vikrant, Sharma, Ratnesh K, Anvikar, Anupkumar R, Chander, Harish
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 09.12.2022
Subjects
bioinformatics
biomarker
breast cancer
ChaC2
glutathione
Oncology
prognosis
breast cancer
ChaC2
biomarker
prognosis
glutathione
bioinformatics
Online AccessGet full text

Cover

More Information
Summary:Breast cancer remains the most commonly diagnosed cancer worldwide and exhibits a poor prognosis. The induction of genetic changes deregulates several genes that increase the disposal towards this life-threatening disease. CHAC2, a member of the glutathione degrading enzyme family has been shown to suppress gastric and colorectal cancer progression, however, the expression of CHAC2 in breast cancer has not been reported. We did an analysis of CHAC2 expression in breast cancer patients from various online tools like UALCAN, GEPIA2, GENT2, TIMER2, and bcGenExminer v4.8. Further, we used the Kaplan-Meier plotter to establish the significance of CHAC2 in BC patient survival and prognosis while TISIDB and TIMER databases were used to investigate the filtration of immune cells. The results showed that CHAC2 levels were high in breast cancer patients and elevated CHAC2 was associated with low overall survival. Taken together, the results of the present study show that like its paralog CHAC1, CHAC2 may also be an important biomarker and could have a potential therapeutic implication in breast cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors have contributed equally to this work and share the first authorship
Reviewed by: Jia Li, University of North Carolina at Charlotte, United States; Hira Iqbal, University of the Punjab, Pakistan
This article was submitted to Breast Cancer, a section of the journal Frontiers in Oncology
Edited by: Nosheen Masood, Fatima Jinnah Women University, Pakistan
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.1058931